Can I get it?
Not for this use. Qsymia has no EU authorisation for it, so it cannot be prescribed or dispensed here for that purpose.
Why buying it online is risky
Qsymia · Charleroi
Qsymia in Charleroi: what you should know.
NOT AVAILABLE IN THE EUQsymia has no EU marketing authorisation for this use.
We don't prescribe it today, but our doctors can review your case and propose an equivalent weight management treatment with EU approval and clinical evidence.
€25/month (billed €25 every 28 days)Full refund if a review is not approved
IN PLAIN TERMS
What Qsymia is, and how to get treatment
Qsymia is the United States brand name for a capsule that combines phentermine and topiramate; it was approved there in July 2012. In Europe the same product is called Qsiva, and its history is complicated. There is no EU-wide approval: the European Medicines Agency refused the Europe-wide application in 2013 because of concerns about long-term effects on the heart, on mood and on memory and attention. The manufacturer later obtained national approvals through a separate route led by Sweden, and the product is on the market in a small number of northern European countries — Sweden, Denmark, Finland and Poland, plus Norway and Iceland. In most EU countries, including Spain, it is not authorised, so a doctor there cannot prescribe it.
Qsymia has no EU marketing authorisation for this use. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.
What can I take instead?
Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits you.
Read about SemaglutideWhat do the studies show?
Every trial behind Qsymia is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.
Jump to the studiesLocal consultation facts
Can I get Qsymia in Charleroi?
Not through Hi-Doctor. Hi-Doctor does not prescribe Qsymia. People in Charleroi, Belgium, can request an online consultation for Weight loss with a licensed EU doctor, who may recommend an available option when clinically appropriate. If approved, the EU prescription arrives as a PDF for a pharmacist in Belgium, who dispenses the locally marketed equivalent with the prescribed active ingredient.
Availability
Hi-Doctor does not prescribe Qsymia. The links below show options in Weight loss that our doctors can assess.
- Country
- Belgium
- Language of service
- Spanish and English
- Prescription turnaround
- In less than 4 hours on average, only if the doctor approves
- Honoured locally
- PDF honoured locally for the prescribed active ingredient
How the EU prescription works where you are: In Belgium, show the approved prescription PDF to a pharmacist. They honour it under EU cross-border rules and dispense the locally marketed equivalent with the prescribed active ingredient.
TREATMENT OPTIONS
Available medical weight-management options
A licensed doctor decides case by case. We never prescribe without evaluation.
Rx · GLP-1
Prescription only
Semaglutide (Wegovy / Ozempic)
Weekly GLP-1 receptor agonist. A doctor may prescribe it if your BMI and history match the indications. Requires follow-up.
Weekly injection pen
€25/month
Rx · GLP-1 / GIP
Prescription only
Tirzepatide (Mounjaro)
Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities and the patient's BMI.
Weekly injection pen
€25/month
Rx · GLP-1
Prescription only
Liraglutide (Saxenda)
Daily GLP-1 agonist. Indicated in selected patients with elevated BMI after medical evaluation.
Daily injection pen
€25/month
Rx · lipase inhibitor
Prescription only
Orlistat 120mg
Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider based on your history.
Capsules
€25/month
Rx · oral GLP-1
Prescription only
Rybelsus (oral semaglutide)
A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.
Daily tablets
€25/month
You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.
WHAT IT COSTS
One plan, reviewed by a doctor.
Weight loss
ONGOING PLAN
€25/month
Billed €25 every 28 days · cancel anytime
28-day treatment cycle
For ongoing treatment and doctor-reviewed renewals.
Renewals reviewed by your doctor
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- First consultation included
- Renewals reviewed by your doctor
- Ongoing care with your doctor
- Cancel anytime
Full refund if a review is not approved
If a review is not approved, we refund that period's €25 fee and cancel the plan.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
VERIFIED EVIDENCE
Qsymia: evidence and regulatory guide.
WHAT IT IS
How it works
A once-daily capsule combining phentermine, which dampens appetite, with a slow-release form of topiramate, an epilepsy and migraine medicine that also reduces how much people want to eat.
- Noradrenaline release (phentermine)
- GABA-A receptors
- AMPA/kainate glutamate receptors
- Carbonic anhydrase
DEVELOPMENT STAGE
Not marketed in the EU
Trial register1 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| CONQUERNCT00553787 | Adults aged 18-70 with a BMI of 27-45 and two or more weight-related conditions | 2,487 | Read out | 2011-04-16 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352. doi:10.1016/S0140-6736(11)60205-5| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| Phentermine 7.5 mg / topiramate 46 mg daily | −7.8% body weight | 56 |
| Phentermine 15 mg / topiramate 92 mg daily | −9.8% body weight | 56 |
| Placebo | −1.2% body weight | 56 |
CONQUER ran for 56 weeks in 93 centres in the United States only; when the European Medicines Agency reviewed this programme it judged that a cardiovascular outcomes trial would be needed before it could accept the long-term safety of the combination, and that trial has not been published.
Sources
Last reviewed 2026-07-27
- EMA — Qsiva: refusal of marketing authorisation (EMEA/H/C/002350)
- EMA — Questions and answers on the refusal of the marketing authorisation for Qsiva
- Swedish Medical Products Agency — Qsiva Public Assessment Report, procedure SE/H/1963/01-04/DC, finalised 22 December 2020
- VIVUS — commercialisation of QSIVA in Sweden, Denmark, Finland, Iceland, Norway and Poland (October 2024)
- Lancet — CONQUER trial
- FDA — Qsymia prescribing information
- ClinicalTrials.gov · NCT00553787
NAMED SAFETY SIGNALS
What has been reported with Qsymia.
Dry mouth
Reported by 21% on the higher dose and 13% on the lower dose in CONQUER, versus 2% on placebo.
Pins and needles (paraesthesia)
Reported by 21% on the higher dose and 14% on the lower dose, versus 2% on placebo.
Constipation
Reported by 17% on the higher dose and 15% on the lower dose, versus 6% on placebo.
Dizziness
Reported by 10% on the higher dose and 7% on the lower dose, versus 3% on placebo.
Insomnia
Reported by 10% on the higher dose and 6% on the lower dose, versus 5% on placebo.
Depression and anxiety
Depression-related events in 7% on the higher dose versus 4% on placebo; anxiety-related events in 8% versus 3% on placebo. The EMA specifically cited long-term psychiatric effects from topiramate when it refused the EU-wide application.
Effects on the heart and circulation
The EMA's committee refused the EU-wide application partly because phentermine is known to increase heart rate and its long-term effects on the heart and blood vessels are not clear.
Risk in pregnancy
Topiramate is known to cause birth defects and has been the subject of an EU safety referral; this combination must not be used in pregnancy and effective contraception is required.
UNAPPROVED PRODUCTS ONLINE
Why buying Qsymia online is not a shortcut.
No doctor in the EU can prescribe it for this use — including ours. It may be authorised in another country, or for a different condition.
Check the EU common logo
A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.
How the EU common logo worksFREQUENTLY ASKED QUESTIONS
Questions about Qsymia.
OTHER WEIGHT LOSS TREATMENTS